Madrigal Pharmaceuticals has a first mover advantage in the huge MASH market due to the approval of Rezdiffra. Read whether I ...

Since its historic FDA approval in March 2024 as the first medication for the treatment of the prevalent liver disease ...

In a new study, Ozempic - a drug sold to help with obesity and diabetes - is attributed to helping this disease.

Q1 2025 Management View CEO Bill Sibold highlighted the momentum of Rezdiffra’s US launch, reporting $137 million in net sales for Q1 2025, reflecting a 33% increase quarter-over-quarter despite ...

Madrigal Pharmaceuticals MDGL reported first-quarter 2025 loss of $3.32 per share, narrower than the Zacks Consensus Estimate ...

Rezdiffra sales reached $137 million for the quarter, beating consensus analyst estimates by more than $20 million and ...

Tina Ventura; Chief Investor Relations Officer; Madrigal Pharmaceuticals, Inc. Bill Sibold; Chief Executive Officer & Director; Madrigal Pharmaceuticals, Inc. Mardi Dier; Chief Financial Officer; ...

First-quarter 2025 Rezdiffra™ (resmetirom) net sales of $137.3 million As of March 31, 2025, more than 17,000 patients on Rezdiffra Two-year compensated MASH cirrhosis (F4c) data from MAESTRO ...

Madrigal Pharmaceuticals Inc (MDGL) reports a 33% increase in net sales and significant patient growth, while navigating ...